Gyre Therapeutics, Inc. (NASDAQ:GYRE) Sees Significant Growth in Short Interest

Gyre Therapeutics, Inc. (NASDAQ:GYRE) was the target of a significant growth in short interest during the month of December. As of December 15th, there was short interest totalling 832,200 shares, a growth of 51.5% from the November 30th total of 549,400 shares. Based on an average trading volume of 78,700 shares, the short-interest ratio is currently 10.6 days. Currently, 3.8% of the company’s shares are sold short.

Hedge Funds Weigh In On Gyre Therapeutics

Hedge funds have recently bought and sold shares of the company. FMR LLC acquired a new stake in Gyre Therapeutics during the 3rd quarter worth about $47,000. Barclays PLC boosted its position in shares of Gyre Therapeutics by 281.8% during the 3rd quarter. Barclays PLC now owns 9,288 shares of the company’s stock valued at $116,000 after purchasing an additional 6,855 shares in the last quarter. Rhumbline Advisers acquired a new stake in Gyre Therapeutics during the second quarter worth approximately $123,000. Renaissance Technologies LLC bought a new stake in Gyre Therapeutics in the second quarter worth approximately $166,000. Finally, Bank of New York Mellon Corp acquired a new position in Gyre Therapeutics in the second quarter valued at approximately $218,000. Institutional investors own 23.99% of the company’s stock.

Gyre Therapeutics Stock Performance

Gyre Therapeutics stock opened at $12.45 on Monday. Gyre Therapeutics has a 52-week low of $8.26 and a 52-week high of $27.45. The firm has a 50 day moving average price of $12.71 and a two-hundred day moving average price of $12.66.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.